Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 3

3(37.5%)

Phase 1

2(25.0%)

8Total

Phase 2(3)

Phase 3(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06024421Phase 1Recruiting

Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Role: collaborator

NCT05777967Phase 3Unknown

Efficacy and Safety of FF-31501 in Meniscus Tear Patients

Role: lead

NCT04191486Phase 2Completed

Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Role: lead

NCT00965757Phase 3Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Role: collaborator

NCT04373733Phase 3Completed

Early Intervention in COVID-19: Favipiravir Verses Standard Care

Role: collaborator

NCT02079909Phase 2Completed

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

Role: lead

NCT02693197Phase 1Completed

PK Study of T-817 in Subjects With Hepatic Impairment

Role: lead

NCT00663936Phase 2Completed

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

All 8 trials loaded